HTG MOLECULAR DIAGNOSTICS IN's ticker is HTGM and the CUSIP is 40434H104. A total of 41 filers reported holding HTG MOLECULAR DIAGNOSTICS IN in Q1 2018. The put-call ratio across all filers is - and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q1 2018 | $5,000 | – | 1,500 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Stonepine Capital Management, LLC | 2,675,889 | $6,797,000 | 5.97% |
| PERKINS CAPITAL MANAGEMENT INC | 449,950 | $1,143,000 | 0.89% |
| Diametric Capital, LP | 116,754 | $297,000 | 0.23% |
| Granahan Investment Management | 924,300 | $2,348,000 | 0.17% |
| Requisite Energy Fund I LP | 100,000 | $254,000 | 0.10% |
| Requisite Capital Management, LLC | 100,000 | $254,000 | 0.10% |
| B. Riley Wealth Advisors, Inc. | 250,000 | $635,000 | 0.09% |
| Kalos Management, Inc. | 74,420 | $179,000 | 0.09% |
| Crow Point Partners, LLC | 65,475 | $164,000 | 0.03% |
| ARDSLEY ADVISORY PARTNERS LP | 35,000 | $89,000 | 0.02% |